Intuitive Surgical, a maker of robotic-assisted minimally invasive surgery, says the United States Food and Drug Administration has provided clearance for the company’s da Vinci Xi Single-Site instruments and accessories.
Intuitive Surgical’s Single-Site technology enables surgeons to operate through a single incision in the patient’s umbilicus during cholecystectomy, benign hysterectomy and salpingo-oophorectomy procedures.
“The da Vinci Xi was designed to seamlessly integrate advanced and future technologies and we are extremely pleased to further expand our line of product offerings with the clearance of Single-Site instruments and accessories,” said Sal Brogna, executive vice president, product operations, Intuitive Surgical. “Single-Site technology adds great versatility to the da Vinci Xi by enabling both single port and multi-port surgery on a single system.”
Since receiving FDA clearance in 2011, Single-Site technology for the da Vinci Si Surgical System has become the most prominent robotic-assisted single-port platform on the market. The da Vinci Xi Surgical System improves upon this platform with new technology, access, and functionality, including:
- Improved Vision: The da Vinci Xi 8 mm endoscope provides the surgeon a brighter, higher resolution view of the surgical field with integrated Firefly fluorescence imaging to highlight specific tissues such as vessels and bile ducts.
- Easier Setup: A single-fin attachment system makes docking easier and faster with added Single-Site features like guided setup to improve OR team usability.
- Great Patient Access: The boom-mounted architecture of the da Vinci Xi Surgical System improves access around the patient with redesigned arms to provide greater range of motion.
The Single-Site product is immediately available for order, with rollout occurring in Q1 of 2016.
